RaNA acquires mRNA platform from Shire

RaNA Therapeutics Inc. (Cambridge, Mass.) said it acquired the MRT mRNA therapeutic platform from Shire plc (LSE:SHP; NASDAQ:SHPG). The platform enables mRNA replacement, which can correct mutations or defects within RNA.

CEO Ronald Renaud told BioCentury the acquisition will allow RaNA to reach the clinic sooner than previously planned. The company hopes that in 12-18 months, it can begin clinical studies of two lead mRNA therapeutics programs to treat cystic fibrosis and urea cycle disorders. ...